Evidence map›Paper›PMID 30068560›Full record

ArticlemSphere2018

A Novel

Esther Ndungo, Arlo Randall, Tracy H Hazen, Dane A Kania, Krista Trappl-Kimmons, Xiaowu Liang, Eileen M Barry, Karen L Kotloff, Subhra Chakraborty, Sachin Mani and 2 more

Open access · goldAbstract read
In one paragraph

Article in mSphere, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 45 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Multifunctional antibody responses from a primateScience translational medicine · 2026
    Article
  4. Article
  5. Article
  6. Development of a NovelVaccines · 2026
    Article
  7. Development of an 8-valentFrontiers in immunology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Vaccines · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. TestingPharmaceutics · 2024
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Esther NdungoCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0002-9975-7032
Arlo RandallAntigen Discovery, Inc., Irvine, California, USA.
Tracy H HazenInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Dane A KaniaInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Krista Trappl-KimmonsAntigen Discovery, Inc., Irvine, California, USA.
Xiaowu LiangAntigen Discovery, Inc., Irvine, California, USA.
Eileen M BarryCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Karen L KotloffCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Subhra ChakrabortyDepartment of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Sachin ManiPATH, Washington, District of Columbia, USA.
David A RaskoInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, Maryland, USA drasko@som.umaryland.edu mpasetti@som.umaryland.edu.ORCID 0000-0002-7337-7154
Marcela F PasettiCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA drasko@som.umaryland.edu mpasetti@som.umaryland.edu.ORCID 0000-0003-0894-4009
University of Maryland, Baltimore · USAntigen Discovery (United States) · USJohns Hopkins University · USProgram for Appropriate Technology in Health · US

Funding

Technology CoreU19AI110820 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI WHITE, OWEN R · 2014 to 2023
$36.5M
Severe Enteric Disease: Pathogenesis and ResponseU19AI090873 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI KAPER, JAMES B · 2010 to 2014
$7.2M
Serological assays to predict Shigella vaccine efficacyR01AI125841 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PASETTI, MARCELA F · 2016 to 2020
$2.8M
Vaccines and maternally acquired immunity to prevent shigellosis in childrenR01AI117734 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PASETTI, MARCELA F · 2015 to 2019
$2.0M
NIAID NIH HHS R01 AI117734NIAID NIH HHS R01 AI125841NIAID NIH HHS U19 AI090873NIAID NIH HHS U19 AI110820
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Protein Array AnalysisAdministration, OralAntibodies, BacterialAntigens, BacterialDysentery, BacillaryHumansMicroarray AnalysisProteomeShigellaShigella VaccinesVaccines, InactivatedAntibodies, BacterialAntigens, BacterialProteomeShigella VaccinesVaccines, Inactivatedantibodiesproteome microarrayShigellavaccines

Identifiers

PMID30068560
PMCPMC6070737
OpenAlexW2886859874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.